Drugs / Nerindocianine
Nerindocianine
also known as
830-15455 · 830-15455 SODIUM · IRDye 800BK · Irdye 800bk sodium · Nerindocianina · nerindocianine sodium
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03387410 | Apr → Nov 2018 | ureteral disorder | Oxford University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 1/2 | NCT03106038 | Apr 2017 → Nov 2018 | — | Li-Cor, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04636567 | Mar → Jul 2021 | urinary system disorder | Li-Cor, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nerindocianine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04636567 ↗ |
| Known as | 830-15455 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298162 ↗ |
| Known as | 830-15455 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298162 ↗ |
| Known as | IRDye 800BK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03387410 ↗ |
| Known as | Irdye 800bk sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298162 ↗ |
| Known as | Nerindocianina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298162 ↗ |
| Known as | nerindocianine sodium | “Subjects received a single dose of nerindocianine sodium, starting at 0.06-mg/kg body weight and increased/decreased until the near-optimal dose was determined (part A).” PMID 32615331 ↗ Jun 2020 |
| Modality | Diagnostic / imaging agent | “an investigational imaging agent” NCT03106038 ↗ |
| Route | Intravenous | “solution, intravenous, one time administration during surgery.” NCT03106038 ↗ |